Человек, получивший обновление иммунной системы для борьбы с раком

атипичный рост кожи, хронический кашель, инфекция носовых пазух, жидкость в лёгких, вирус в правом глазу и сильная изжога. Но рака не было.

Даже если результат терапии будет 60% в тяжелых случаях, то уже будет огромный успех, раньше и этого не было.

300к сформировалась из неверного прочтения (автором поста) материала
https://www.nytimes.com/2017/07/12/health/fda-novartis-leukemia-gene-medicine.html, в котором нет данных о точной стоимости и сказано лишь "аналитики предсказывают что стоимость индивидуального лечения может превысить 300 000 USD,… Novartis отказывается указывать цену":

Analysts predict that these individualized treatments could cost more than $300,000, but a spokeswoman for Novartis, Julie Masow, declined to specify a price. Although the figure may seem high, people with cancer often endure years of expensive treatment and repeat hospital stays that can ultimately cost even more.… Because the treatment is complex and patients need expert care to manage the side effects, Novartis will initially limit its use to 30 or 35 medical centers.… the treatment, known as CTL019 or tisagenlecleucel… "… We are working on bringing CTL019 to other countries around the world." "
In studies, the process of re-engineering T-cells for treatment sometimes took four months, and some patients were so sick that they died before their cells came back.… At the meeting, Novartis said the turnaround time was now down to 22 days.

Некоторые оценки http://www.fiercebiotech.com/biotech/novartis-gains-speedy-fda-review-for-new-car-t-med-as-kite-race-begins:

Its blockbuster potential will likely come with a blockbuster price: Analysts at Jefferies believe Kite's Axi-Cell, across all indications, could cost up to $300,000 in the U.S., while in Europe, they’re predicting a price tag of $204,000.
These prices have gone up by around $100,000 and $80,000 respectively in recent months, as new data have come in, and are similar to those price tags believed to be applied to Novartis’ med.

https://www.thepharmaletter.com/article/car-t-pricing-decision-looms-large-for-novartis

When setting the price not only of the first drug of its kind to reach the market, but also one that is manufactured for each individual patient, a drugmaker might feel justified in asking for a good return to cover the significant development and manufacturing costs.…
Bloomberg reports that Novartis is looking at multiple options, including using stem cell transplants — which cost as much as $800,000 each – as a yardstick, as it considers a fair rate.
The article also cites the company’s chief executive Joe Jimenez as saying that UK report findings that £583,000 ($750,000) would be a cost-effective price as being in the “right ballpark,” although study author Stephen Palmer, a professor at the University of York, says such an expense is unlikely to be acceptable as a one-time payment.
“CAR-Ts could command a high price because they’re intended as one-time treatments and have shown benefits in some patients who had no other options,” the article adds. “Yet some studies indicate that only about one in three people experience a lasting response. Some sort of pay-for-performance deal may entice insurers to accept higher price tags, because it means they’ll get paid back if the treatment fails.”

https://www.bloomberg.com/news/articles/2017-06-08/novartis-gets-creative-in-pricing-next-generation-cancer-therapy

The two therapies are vying to become the first blockbusters in an emerging field known as CAR-T, in which a patient’s immune cells are extracted and genetically modified to hunt and kill cancer before being returned to the body. Novartis may link the price of its treatment to results in each patient, according to Narasimhan.… “We’re looking at multiple creative options,” Narasimhan said. “We’re still in the forming stages of figuring out what the right approach is going to be.”… Kite may charge $325,000 per treatment, the analyst Nierengarten wrote in a March note. To justify the company’s market value — currently about $4.6 billion — it would need to charge $500,000 per course or capture as much as 50 percent of the market, a scenario that’s possible but unlikely, he said.